News

Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...
Moderna lays off 500 in latest cost-cutting move
The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...
Moderna to cut more than 800 jobs this year as it burns through cash
In a note to employees on Thursday, Moderna Inc. said it was laying off about 10% of its global workforce as part of the ...
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
BioPharma Dive7d
Moderna to lay off 10% of workforce in ‘difficult but necessary step’
In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...
Fierce Pharma6d
Despite ongoing decline, Moderna's Spikevax sales beat expectations in Q2
Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...
Moderna cuts sales forecast on UK revenue delay, shares fall
Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...
Moderna to lay off 10% of workforce
Moderna CEO Stephane Bancel said in a memo to employees that the company expects to reduce its workforce to fewer than 5,000 ...
Moderna plans to slash 10% of workforce as COVID shot sales slow
Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...
Moderna quarterly sales beat Street estimates on COVID booster sales, cost cuts
Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...
Analysts Are Neutral on These Healthcare Stocks: Moderna (MRNA), Twist Bioscience (TWST)
According to TipRanks.com, Richter is a 4-star analyst with an average return of 8.8% and a 42.9% success rate. Richter covers the Healthcare sector, focusing on stocks such as Ultragenyx ...